Clinical trial
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have…
NCT00445692 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00445692 |
|---|---|
| Title | Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma |
| Official title | Maintenance Therapy With Lenalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma |
| Intervention type | Drug |
| Interventions | Clarithromycin, Dexamethasone, Lenalidomide |
| Enrollment | 32 |
| Start date | Jan 10, 2007 |
| Primary completion | Apr 24, 2017 |
| Completion | Apr 24, 2017 |
| First posted | Mar 9, 2007 |
| Last update posted | Nov 13, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: